According to a story from blogs.biomedcentral.com, the findings from the IPF-PRO Registry, which is a US-based registry for idiopathic pulmonary fibrosis patients, were recently published. Patient registries are a critical…
According to a story from MD Magazine, the field of scleroderma treatment has seen some recent developments that could have major implications for how patients manage their disease. The latest…
Preclinical data supporting the efficacy of GKT831 as a potential therapy for cholestatic fibrosis has just been published in the Journal of Hepatology. GKT831 GKT831 is both a NOX1 enzyme and…
According to a story from Boehringer Ingelheim Pharmaceuticals, Inc., the company has recently announced positive results from a phase 3 clinical trial testing the company's drug nintedanib (marketed as Ofev)…
According to a story from PR Newswire, the biopharmaceutical company Respivant Sciences has recently announced that it has dosed the first patient in its phase 2b clinical trial. This trial…
According to a story from mirror.co.uk, Professor Selim Cellek is leading a clinical trial that will test a drug combination designed to treat erectile dysfunction associated with Peyronie's disease, a…
Cedric Rutland, a pulmonologist at Pacific Pulmonary Medical Group has shared his experience, research, and thoughts on cognitive bias in an effort to spread awareness for the issue, and hopefully,…
For years FibroGen has been investigating a drug called pamrevlumab. They believe it could be an effective treatment for Duchenne muscular dystrophy (DMD), pancreatic cancer, and idiopathic pulmonary fibrosis (IPF).…
Nigam Shah and Purvesh Khatri, professors at Stanford University, along with graduate student Madeleine Scott have just announced results from a research study which could be pivotal for those living…
Idiopathic pulmonary fibrosis (IPF) is a rare condition with no known cause and no effective treatments besides a lung transplant. Current therapies focus on slowing progression of the disease but…
According to a story from nbcrightnow.com, pulmonary fibrosis affects hundreds of thousands of people in the US. However, many people still have not heard of the disease and are not…
According to a story from finanznachrichten.de, biotechnology companies are starting to set their sights on treating deadly diseases that are lacking effective treatment options, including some diseases that are considered…
According to a press release from X-Rx Inc., a privately-held American biotechnology company, the Food and Drug Administration has accepted the company's Investigational New Drug (IND) application for X-165, an…
Vogmask is a San Francisco, California based company founded in 2011. They create stylish facial masks to protect wearers from inhalation of particulate and allergens. These types of masks can…
A January 4th post by the Lancet's EBioMedicine headlined the first-in-human pilot study results published by UT Health San Antonio in collaboration with the Mayo Clinic and the Wake Forest School…
Pliant Therapeutics, Inc., a biotechnology company specializing in developing and commercializing treatments for fibrotic diseases, announced on January 3, 2019 through PRNewswire, that it has initiated a Phase 1 first-in-human…
According to a story from Medical Xpress, a collaborative team of scientists from UT Health San Antonio, the Mayo Clinic, and the Wake Forest School of Medicine, have recently released…
The first patient has been dosed in a new clinical trial of an investigational drug for idiopathic pulmonary fibrosis. The drug, called GLPG1205, is being developed by Galapagos, and you…
According to a story from BBC, John Mason, age 80, is one of over 2,000 people in Wales who currently have idiopathic pulmonary fibrosis (IPF), a rare and ultimately lethal…
A report on newsmedical.net details a major grant awarded for the research of idiopathic pulmonary fibrosis (IPF). The grant totals $8.9 million, aiming to fund a program for several years.…
The National Institutes of Health (NIH) have granted the University of Alabama at Birmingham $8.9 million to fund research into an investigational drug for idiopathic pulmonary fibrosis. You can read…
According to a story from EurakAlert!, a group of researchers from the University of Pennsylvania School of Medicine have achieved a major breakthrough for idiopathic pulmonary fibrosis research that will…
CHICAGO, July 19, 2018 – The Pulmonary Fibrosis Foundation (PFF) and monARC Bionetworks have partnered to create the mobile app, PF Health, for individuals living with pulmonary fibrosis (PF). PF Health, now available on Apple App Store (iOS 9.0 or…
According to EurekAlert! Science News, researchers have pinpointed the certain immune cell that further inflames a heart attack. The immune cell, however, comes with good intentions of trying to fix…
According to a story from CheckOrphan, Express Scripts has prepared a Rare Conditions Care Value (RCCV) program. This program is designed to help make the diagnosis and treatment process for…
© Copyright Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
